MedPath

The Türkiye Heart Failure Registry

Recruiting
Conditions
Heart Failure
Registration Number
NCT06707220
Lead Sponsor
Baskent University
Brief Summary

A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
5000
Inclusion Criteria

Presence of heart failure -

Exclusion Criteria

Age <18 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Heart failure hospitalizationFrom enrollment to the end of follow-up period at 12 months
Cardiovascular mortalityFrom enrollment to the end of follow-up period at 12 months
Composite of heart failure hospitalization and cardiovascular mortalityFrom enrollment to the end of follow-up period at 12 months
Secondary Outcome Measures
NameTimeMethod
All-cause mortalityFrom enrollment to the end of follow-up period at 12 months

Trial Locations

Locations (1)

Baskent University

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath